Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases.
Sang-A KimJi-Won KimKoung Jin SuhWon ChangJin Won KimHeung-Kwon OhJai Young ChoDuck-Woo KimSukki ChoJee Hyun KimKwhanmien KimSung-Bum KangSanghoon JheonKeun-Wook LeePublished in: Journal of cancer research and clinical oncology (2020)
A substantial proportion of patients could receive CS after cetuximab or bevacizumab plus FOLFIRI chemotherapy. R0-resected patients had excellent overall survival, although 80.1% of them eventually experienced recurrence. Some patients could achieve durable disease-free state.